Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.

Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T

Nutrients11 Feb 2022Cited by 58 (Europe PMC)

PMID35215405PMCIDPMC8877443DOI10.3390/nu14040755PepBankPUB-35215405

Summary

Deteriorating sleep quality and physical or mental fatigue in older adults leads to decreased quality of life and increased mortality rates. This study investigated the effects of the time-dependent intake of nicotinamide mononucleotide (NMN) on sleep quality, fatigue, and physical performance in older adults. This randomized, double-blind placebo-controlled study evaluated 108 participants divided into four groups (NMN_AM; antemeridian, NMN_PM; post meridian, Placebo_AM, Placebo_PM). NMN (250 mg) or placebo was administered once a day for 12 weeks. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index. Fatigue was evaluated using the "Jikaku-sho shirabe" questionnaire. Grip strength, 5-times sit-to-stand (5-STS), timed up and go, and 5-m habitual walk were evaluated to assess the physical performance. Significant interactions were observed between 5-STS and drowsiness. 5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention. The NMN_PM group demonstrated the largest effect size for 5-STS (d = 0.72) and drowsiness (d = 0.64). Overall, NMN intake in the afternoon effectively improved lower limb function and reduced drowsiness in older adults. These findings suggest the potential of NMN in preventing loss of physical performance and improving fatigue in older adults.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

01HumanNot a test of NMN (nicotinamide mononucleotide) aloneRandomized controlled trialEfficacy outcome
In older adults, sit-to-stand performance improved in all groups, including placebo.
In plain wordsIn older adults, sit-to-stand performance improved in every group, including placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Decrease5-times sit-to-stand change
Study
n = 108
Comparator
Pre-intervention
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind placebo-controlled study evaluated 108 participants divided into four groups (NMN_AM; antemeridian, NMN_PM; post meridian, Placebo_AM, Placebo_PM).
Summary · context
NMN (250 mg) or placebo was administered once a day for 12 weeks.
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Show in the study text Report a problemFND-3521540501
02HumanNot a test of NMN (nicotinamide mononucleotide) aloneRandomized controlled trialEfficacy outcome
In older adults, drowsiness improved in both afternoon NMN and afternoon placebo groups during and after intervention.
In plain wordsIn older adults, drowsiness improved with both afternoon NMN and afternoon placebo compared with pre-intervention.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseDrowsiness change
Study
n: not reported in source
Comparator
Pre-intervention
Outcome group
Sleep · Sleep
Source sentences
Summary
5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, double-blind placebo-controlled study evaluated 108 participants divided into four groups (NMN_AM; antemeridian, NMN_PM; post meridian, Placebo_AM, Placebo_PM).
Summary · context
NMN (250 mg) or placebo was administered once a day for 12 weeks.
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Show in the study text Report a problemFND-3521540502
03HumanNot a test of NMN (nicotinamide mononucleotide) aloneRandomized controlled trialEfficacy outcome
In older adults, afternoon NMN had the largest sit-to-stand effect size, although all groups improved.
In plain wordsIn older adults, afternoon NMN had the largest sit-to-stand effect size, although all groups improved.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reported5-times sit-to-stand effect size
Study
n: not reported in source
Comparator
Other study groups
Outcome group
Exercise and physical function · Whole body
Measurements
Effect size
0.72 d
NMN_PM 5-STS
Source sentences
Summary
The NMN_PM group demonstrated the largest effect size for 5-STS (d = 0.72) and drowsiness (d = 0.64).
3 context sentences(design, population, supporting numbers)
Summary · context
5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention.
Summary · context
This randomized, double-blind placebo-controlled study evaluated 108 participants divided into four groups (NMN_AM; antemeridian, NMN_PM; post meridian, Placebo_AM, Placebo_PM).
Summary · context
NMN (250 mg) or placebo was administered once a day for 12 weeks.
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Show in the study text Report a problemFND-3521540503
04HumanNot a test of NMN (nicotinamide mononucleotide) aloneRandomized controlled trialEfficacy outcome
In older adults, afternoon NMN had the largest drowsiness effect size, although afternoon placebo also improved drowsiness.
In plain wordsIn older adults, afternoon NMN had the largest drowsiness effect size, although afternoon placebo also improved drowsiness.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedDrowsiness effect size
Study
n: not reported in source
Comparator
Other study groups
Outcome group
Sleep · Sleep
Measurements
Effect size
0.64 d
NMN_PM drowsiness
Source sentences
Summary
The NMN_PM group demonstrated the largest effect size for 5-STS (d = 0.72) and drowsiness (d = 0.64).
3 context sentences(design, population, supporting numbers)
Summary · context
5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention.
Summary · context
This randomized, double-blind placebo-controlled study evaluated 108 participants divided into four groups (NMN_AM; antemeridian, NMN_PM; post meridian, Placebo_AM, Placebo_PM).
Summary · context
NMN (250 mg) or placebo was administered once a day for 12 weeks.
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Show in the study text Report a problemFND-3521540504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.